Cost effectiveness of exemestane versus tamoxifen in post-menopausal women with early breast cancer in Germany

Breast Care

Volumn 4, Issue 6, 2009, Pages 389-396

  Braun, Sebastian ^a   Mittendorf, Thomas ^a   Menschik, Thomas ^b   Greiner, Wolfgang ^c   Von Der Schulenburg, Johann Matthias ^a  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b PFIZER INC   (United States)

^c BIELEFELD UNIVERSITY   (Germany)

Author keywords

Aromatase inhibitors; Breast cancer; Cost effectiveness; Early stage; Postmenopause

Indexed keywords

EXEMESTANE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SUBSTITUTION; EARLY CANCER; FEMALE; GERMANY; HEALTH CARE; HEALTH CARE COST; HUMAN; OVERALL SURVIVAL; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

EID: 76749132025     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000255840     Document Type: Article

References (28)

1. EBCTCG: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 2005;365:1687-1717.
2. Boccardo F, Rubagotti A, Guglielmini P, Fini A, Paladini G, Mesiti M, Rinaldini M, Scali S, Porpiglia M, Benedetto C, Restuccia N, Buzzi F, Franchi R, Massidda B, Distante V, Amadori D, Sismondi P: Anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006;17(suppl 7):vii10-vii14.
3. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lonning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-570.
4. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97:1262-1271.
5. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J: Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-462.
6. Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 2007; 25:2664-2670.
7. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione- Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-2757. (Pubitemid 43016814)
8. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR; American Society of Clinical Oncology: Technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005;23:619-629.
9. Deutsche Krebsgesellschaft e.V. (DKG) und Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) (eds): Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms, 1. Aktualisierung 2008.
10. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM: A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-1092. (Pubitemid 38298988)
11. Statistisches Bundesamt (ed): Death statistics for Germany [Sterbetafel 2002/2004]. Wiesbaden, 2005.
12. von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, Mittendorf T, Rebscher H, Schoeffski O, Vauth C, Volmer T, Wahler S, Wasem J, Weber C: German recommendations on health economic evaluation - third and updated version of the Hanover Consensus. Value Health 2008; 11:539-544.
13. Carter KJ, Ritchey NP, Castro F, Caccamo LP, Kessler E, Erickson BA, Gawdyda LM: Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach. Med Decis Making 1998;18:213-219.
14. Desch CE, Hillner BE, Smith TJ, Retchin SM: Should the elderly receive chemotherapy for nodenegative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes. J Clin Oncol 1993;1:777-782.
15. Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991;324:160-168.
16. Karnon J, Johnston SRD, Delea TE, Smith RE, Brandman J, Sung JC, Goss PE: Cost-effectiveness of extended adjuvant letrozole after five years of tamoxifen in postmenopausal early breast cancer. Paper presented at the 40th ASCO Annual Meeting, New Orleans, 5-8 June 2004.
17. Kanis JA, Borgström F, Johnell O, Oden A, Sykes D, Jönsson B: Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 2005;16:15-25.
18. Ozanne EM, Esserman LJ: Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis. Cancer Epidemiol Biomarkers Prev 2004;13:2043-2052.
19. Eckman MH, Levine HJ, Pauker SG: Effect of laboratory variation in the prothrombin-time ratio on the results of oral anticoagulant therapy. N Engl J Med 1993;329:696-702.
20. Cykert S, Phifer N, Hansen C: Tamoxifen for breast cancer prevention: a framework for clinical decisions. Obstet Gynecol 2004;104:433-442.
21. Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM: Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003;97:545-553.
22. Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D: Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol 1993;11:44-48.
23. InEK GmbH (ed): German-DRG Browser, Version 2005. Siegburg, 2006.
24. Kassenärztliche Bundesvereinigung (ed): Uniform reimbursement scheme for ambulatory services [Einheitlicher Bewertungsmaßstab (EBM)]. Berlin, 2004.
25. Red Book Service GmbH (ed): Red price list for Germany [Red Book]. Frankfurt/Main, 2004.
26. Lundkvist J, Wilking N, Holmberg S, Jönsson L: Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden. Breast Cancer Res Treat 2007;102:289-299.
27. Risebrough NA, Verma S, Trudeau M, Mittmann N: Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer. Cancer 2007;110:499-508.
28. Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC: Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 2007;10: 367-376.